“Rather than following the traditional drug discovery process, we begin with proof-of-concept data from human interventional studies to identify meaningful microbial signatures. We have a Full-Spectrum Microbiota® (FSM®) product platform that allows for the development of therapies that contain a diverse community of microbiota from healthy human donors, as well as a Rationally-Selected Microbiota® (RSM™) product platform that allows for the development of therapies containing select microbes, grown in pure culture, that we believe are driving successful clinical outcomes.”
“Smith, who has a PhD in microbiology, has devoted much of his adult life to treating and curing C. diff, partly by founding two companies—OpenBiome and Finch Laboratories. The former is basically a non-profit “stool bank” that collects life-giving samples from donors, and the latter is a research and development company working on making the treatment available to all who need it—including in pill form.”
When Smith launched OpenBiome, the entire landscape of CDI treatment changed. Now that he is at Finch Therapeutics, Smith is ready to change the treatment landscapes of many more diseases. “If we could manage this ecosystem and intentionally modulate the composition of this community,” he declares, “we could radically impact the drivers of morbidity and mortality.”
‘Meanwhile, the success of the study in Arizona has prompted America’s Food and Drug Administration (FDA) to look into the matter. A firm called Finch Therapeutics Group, based in Massachusetts, hopes to commercialise the use of MTT as a treatment for autism and the FDA has now granted this effort “fast track” status, which should speed up the review process.’
“Over the past decade, tens of thousands of Americans with C. diff have been cured through fecal transplants, often with a single dose that can bring patients back from the brink of death. The treatment has more than an 80 percent success rate, according to severalstudies, and many patients feel better within hours of receiving the procedure, which is usually administered through colonoscopy or capsules containing desiccated fecal matter.”
CEO Mark Smith describes the vast potential of the microbiome and Finch’s therapeutic platforms:
“We think the microbiome is really fundamental to many aspects of who we are, how our immune systems function, how we regulate our metabolism and how we think and feel,’ says Smith, who predicts ‘broad potential across a number of therapeutic areas.”
Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema.
Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors. “We are delighted to have Jo and Dom join our Board of Directors,” said Mark Smith, PhD, CEO of Finch. “The extensive drug development and corporate finance experience that Jo and Domenic respectively bring to Finch will be very valuable as we advance our pipeline of microbiome therapeutics for recurrent C. difficile infection, autism spectrum disorder, ulcerative colitis, and other conditions linked to a disrupted gut microbiome.”
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutic platform company, announced today that Zain Kassam, MD, MPH, has been appointed Chief Medical Officer (CMO) effective September 1, 2019. Dr. Kassam will lead the advancement of Finch’s microbiome therapeutics for recurrent C. difficile infection, ulcerative colitis, and autism spectrum disorder through the clinical development and regulatory submission process.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors.
On June 13, FDA reported that an immunocompromised patient treated with FMT died from a drug resistant infection. Importantly, this patient was not treated by Finch or our collaborator, OpenBiome. The FDA has communicated new mandatory screening standards, which Finch already exceeds. As a result, there is no impact on Finch’s work and our PRISM 3 and PRISM-EXT studies continue uninterrupted.
The infection occurred in a high-risk patient that received material from a donor that was not screened for a common drug resistant pathogen, resulting in exposure and subsequent infection. Finch has a thorough screening program which incorporates a panel of 30+ laboratory tests, including the agent associated with this adverse event, as part of our commitment to patient safety.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children with Autism Spectrum Disorder (ASD). Fast Track designation is intended to facilitate development and expedite review of therapies designed to treat serious conditions and fill an unmet medical need.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational drug CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.
Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms.
Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that it has appointed Ulrich Thienel, Ph.D., M.D., as Chief Medical Officer and Gregory Perry as Chief Financial Officer.
Finch Therapeutics Group, Inc. (Finch), a privately held microbiome therapeutics company, announced today the successful close of an oversubscribed $36 million Series B financing, bringing the total capital raised since the Company’s launch to $77 million.
The new entity, Finch Therapeutics Group, combines Crestovo’s extensive IP assets and late-stage candidate for recurrent C. difficile infections, CP101, an oral Full-Spectrum Microbiota product, with Finch’s commercial-scale manufacturing capabilities, discovery platform for developing Rationally-Selected Microbiota therapies and significant product pipeline.